A study investigated the effectiveness of combining recombinant methioninase (rMETase), which targets methionine dependence in cancer cells, with a first-line melanoma drug temozolomide (TEM) in a patient-derived orthotopic xenograft (PDOX) mouse model of BRAF V600E mutant melanoma. This evidence concerns the gene BRAF and melanoma.